- Deutsche Bank is out with some commentary on Gilead (GILD -0.6%) two weeks into the Sovaldi launch.
- IMS data reportedly show 834 new patient starts as of the week ending December 20.
- "Assuming new starts increasing to 1000/wk by end of the year and gross to net of 15%, we [calculate] Q4 sales at $61M. If new starts rise to 2000/wk by year end, assuming a gross to net of 15%, we [calculate] Q4 sales at $98M," analyst Robyn Karnauskas notes.
- Buy rating maintained.
- Price target is $95.
Deutsche still bullish on Gilead after Sovaldi launch
Dec 31 2013, 10:36 ET